A 96 week study comparing the antiviral efficacy and safety of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with fixed dose tenofovir-emtricitabine [emtricitabine/tenofovir-disoproxil-fumarate] in HIV-1 infected treatment in naive subjects

Trial Profile

A 96 week study comparing the antiviral efficacy and safety of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with fixed dose tenofovir-emtricitabine [emtricitabine/tenofovir-disoproxil-fumarate] in HIV-1 infected treatment in naive subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms CASTLE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Feb 2014 Results from a sub-group analysis published in the Clinical Drug Investigation.
    • 20 Jul 2011 BMD outcomes from a subgroup analysis presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top